Bio-Rad Reports Again as the Least-Shorted Name in Its Peer Group

Bio-Rad Laboratories carries less short-selling pressure into its November 4 results than any closely correlated name in the life science tools sector. Among peers, Agilent Technologies and Repligen have both sustained measurably higher short interest through 2026. Bio-Rad's own lending market registers zero utilization across every reading taken this year, confirmed by FINRA's September 30 settlement data showing just one thousand shares short and a single day's volume required to cover. That is not a bullish signal in itself; it means price discovery around the print runs entirely through ordinary buyers and sellers, with no short-covering dynamic to amplify any move in either direction.

The more live debate is between the stock's price momentum and where analysts believe fair value sits. Bio-Rad has gained roughly 26% year to date, closing at $379.50 on October 27, a level that a recent ORTEX stock note flagged as trading above the consensus analyst view. The EPS surprise factor score ranks in the 98th percentile, meaning the company has consistently beaten estimates by a wide margin. The forward EPS momentum reading of 166.76 reflects sharp upward revisions. Against that, the analyst price-target discount implies the Street sees the stock as ahead of itself, a tension the August print did nothing to resolve: Bio-Rad jumped 8.3% on those results and held the gain over the following five days.

The November print is therefore less a test of Bio-Rad's operational direction, which the momentum and EPS data broadly support, and more a test of whether the current valuation can absorb whatever the company reports without the gap between price and consensus target widening further.